Literature DB >> 17715167

Influenza- and respiratory syncytial virus-associated mortality and hospitalisations.

A G S C Jansen1, E A M Sanders, A W Hoes, A M van Loon, E Hak.   

Abstract

The aim of the current study was to estimate influenza- and respiratory syncytial virus (RSV)-associated mortality and hospitalisations, especially the influenza-associated burden among low-risk individuals < or =65 yrs old, not yet recommended for influenza vaccination in many European countries. Retrospectively during 1997-2003, Dutch national all-cause mortality and hospital discharge figures and virus surveillance data were used to estimate annual average influenza- and RSV-associated excess mortality and hospitalisation using rate difference methods. Influenza virus active periods were significantly associated with excess mortality among 50-64-yr-olds and the elderly, but not in younger age categories. Influenza-associated hospitalisation was highest and about equal for 0-1-yr-olds and the elderly, and also significant for low-risk adults. Hospitalisation among children was mostly due to respiratory conditions, and among adults cardiovascular complications were frequent. RSV-active periods were associated with excess mortality and hospitalisation among the elderly. The highest RSV-related excess hospitalisation was found in 0-1-yr-olds. Influenza-associated mortality was demonstrated in 50-64-yr-olds. Among low-risk individuals < or =65 yrs of age, influenza-associated hospitalisation rates were highest for 0-4-yr-olds, but also significant for 5-64-yr-olds. These data may further support extension of recommendations for influenza vaccination to include younger low-risk persons. The respiratory syncytial virus-associated burden was highest for young children but also substantial for the elderly.

Entities:  

Mesh:

Year:  2007        PMID: 17715167     DOI: 10.1183/09031936.00034407

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  59 in total

Review 1.  The success of microneedle-mediated vaccine delivery into skin.

Authors:  Sarah Marshall; Laura J Sahm; Anne C Moore
Journal:  Hum Vaccin Immunother       Date:  2016-04-06       Impact factor: 3.452

2.  Heterogeneity in Estimates of the Impact of Influenza on Population Mortality: A Systematic Review.

Authors:  Li Li; Jessica Y Wong; Peng Wu; Helen S Bond; Eric H Y Lau; Sheena G Sullivan; Benjamin J Cowling
Journal:  Am J Epidemiol       Date:  2018-02-01       Impact factor: 4.897

3.  Ephedrannin B exerts anti-viral and anti-inflammatory properties in BEAS-2B cells infected with respiratory syncytial virus.

Authors:  Shu Hou; Xiaoyan Xu; Yating Wang; Yan Yang
Journal:  J Biosci       Date:  2020       Impact factor: 1.826

4.  Impaired immune response to vaccination against infection with human respiratory syncytial virus at advanced age.

Authors:  Teun Guichelaar; Jeroen Hoeboer; Myra N Widjojoatmodjo; Sylvia S N Reemers; Cécile A C M van Els; Rob Otten; Yvonne van Remmerden; Jolande Boes; Willem Luytjes
Journal:  J Virol       Date:  2014-06-11       Impact factor: 5.103

5.  Rates of hospitalizations for respiratory syncytial virus, human metapneumovirus, and influenza virus in older adults.

Authors:  Kyle Widmer; Yuwei Zhu; John V Williams; Marie R Griffin; Kathryn M Edwards; H Keipp Talbot
Journal:  J Infect Dis       Date:  2012-04-23       Impact factor: 5.226

6.  Clinical characteristics and risk factors of severe respiratory syncytial virus-associated acute lower respiratory tract infections in hospitalized infants.

Authors:  Xiao-Bo Zhang; Li-Juan Liu; Li-Ling Qian; Gao-Li Jiang; Chuan-Kai Wang; Pin Jia; Peng Shi; Jin Xu; Li-Bo Wang
Journal:  World J Pediatr       Date:  2014-12-17       Impact factor: 2.764

Review 7.  Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis.

Authors:  Harish Nair; D James Nokes; Bradford D Gessner; Mukesh Dherani; Shabir A Madhi; Rosalyn J Singleton; Katherine L O'Brien; Anna Roca; Peter F Wright; Nigel Bruce; Aruna Chandran; Evropi Theodoratou; Agustinus Sutanto; Endang R Sedyaningsih; Mwanajuma Ngama; Patrick K Munywoki; Cissy Kartasasmita; Eric A F Simões; Igor Rudan; Martin W Weber; Harry Campbell
Journal:  Lancet       Date:  2010-05-01       Impact factor: 79.321

8.  Prospective population-based study of RSV-related intermediate care and intensive care unit admissions in Switzerland over a 4-year period (2001-2005).

Authors:  T M Berger; C Aebi; A Duppenthaler; M Stocker
Journal:  Infection       Date:  2008-12-09       Impact factor: 3.553

Review 9.  Respiratory syncytial virus--a comprehensive review.

Authors:  Andrea T Borchers; Christopher Chang; M Eric Gershwin; Laurel J Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2013-12       Impact factor: 8.667

10.  Broadly neutralizing influenza hemagglutinin stem-specific antibody CR8020 targets residues that are prone to escape due to host selection pressure.

Authors:  Kannan Tharakaraman; Vidya Subramanian; David Cain; Viswanathan Sasisekharan; Ram Sasisekharan
Journal:  Cell Host Microbe       Date:  2014-05-14       Impact factor: 21.023

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.